Reyataz and Overdose - a phase IV clinical study of FDA data

Summary:

Overdose is reported as a side effect among people who take Reyataz (atazanavir sulfate), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Norvir, and have Stress and anxiety.

The phase IV clinical study analyzes which people have Overdose when taking Reyataz. It is created by eHealthMe based on reports of 11,228 people who have side effects when taking Reyataz from the FDA, and is updated regularly.

What is Reyataz?

Reyataz has active ingredients of atazanavir sulfate. It is often used in hiv infection. eHealthMe is studying from 11,386 Reyataz users. Check the latest studies of Reyataz.

What is Overdose?

Overdose is found to be associated with 2,219 drugs and 2,471 conditions by eHealthMe. Check the latest studies of Overdose.

On Jul, 10, 2026

11,228 people reported to have side effects when taking Reyataz.
Among them, 61 people (0.54%) have Overdose.

Among these 61 people:

How long have people been on Reyataz when they have Overdose? *

What is the gender of people who have Overdose when taking Reyataz? *

female: 34.48 %
male: 65.52 %

What is the age of people who have Overdose when taking Reyataz? *

What are other drugs people take besides Reyataz? *

What are other side effects people have besides Overdose? *

Renal Impairment (severely reduced kidney function): 8 people, 13.11%
Weakness: 7 people, 11.48%
Suicide Attempt: 4 people, 6.56%
Oxygen Saturation Decreased: 4 people, 6.56%
Dizziness: 4 people, 6.56%
Sedation: 4 people, 6.56%
Speech Impairment (Adult) (inability to speak (adult)): 4 people, 6.56%
Loss Of Consciousness: 4 people, 6.56%
Blood Creatinine Increased: 4 people, 6.56%
Agitation (state of anxiety or nervous excitement): 4 people, 6.56%

What are the existing conditions these people have? *

Hepatitis C: 3 people, 4.92%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 3 people, 4.92%
Depression: 3 people, 4.92%
Stress And Anxiety: 3 people, 4.92%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 2 people, 3.28%
Haemoglobin Decreased: 2 people, 3.28%
Mania (a state of abnormally elevated or irritable mood): 2 people, 3.28%
Itching: 2 people, 3.28%
Transplant Rejection (a transplant material is not worked): 1 person, 1.64%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 1.64%

* Approximation only. Some reports may have incomplete information.

Do you take Reyataz and have Overdose?

- Check whether Overdose is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Reyataz:

Reyataz (11,386 reports)

Overdose treatments and more:

Overdose (229,245 reports)

Browse all side effects of Reyataz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Overdose:

Overdose (2,219 drugs)

Browse all the conditions that are associated with Overdose:

Overdose (2,471 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on atazanavir sulfate (the active ingredients of Reyataz) and Reyataz (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.